4C-D Stats & Data

4C-D (Ariadne) is a rare α-ethyl phenethylamine described in PiHKAL with only threshold-level psychedelia at ~20–30 mg; detailed modern human data remain sparse. Identity confusion has occurred in community discussions (e.g., fears of DOM/DOx mislabel), so treating any unverified sample as potentially long-acting is prudent until lab-checked. Community reports since ~2018–2024 describe mild stimulation, warmth, sociability and low visuals, with many noting that higher single oral doses (≈40–150 mg) were needed for clear effects, implying a wide potency variance and/or material variability. Onset can be slow and subtle, increasing the temptation to redose; wait at least 3 hours before considering any change to reduce overdose/stacking risk. Insufflation has been reported as harsh on the nose/throat with little benefit compared to oral dosing; oral remains the most documented route. As a phenethylamine, transient increases in heart rate and blood pressure are plausible; those with cardiovascular, seizure or serious psychiatric histories should avoid or use extra caution. Strong serotonergic combinations (MAOIs, tramadol, DXM, methylene blue/linezolid, heavy SSRI/SNRI stacking) raise serotonin toxicity risk; lithium has a history of dangerous interactions with psychedelics and should be strictly avoided. Because it is obscure, authenticity and purity are the primary hazards—use professional drug checking where available; if unavailable, start with sub-milligram allergy tests, then single small doses using an accurate milligram scale (or volumetric dosing) and never redose quickly. There are no human pharmacokinetic studies; half-life is unknown, and total effect length should not be assumed to equal elimination half-life. Long-term neurotoxicity or cardiotoxicity data do not exist; prudent spacing between experiences (weeks) and conservative dosing are advisable.